EGFR T790M突变在非小细胞肺癌中的研究进展

Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer

摘要: 表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）可以改善EGFR阳性非小细胞肺癌（NSCLC）患者的预后，但在TKIs的应用中，基因检测发现EGFR T790M突变的患者越来越多，这一现象的发生对患者治疗及预后产生了严重的影响。本文综述了T790M突变与一、二、三代EGFR-TKIs的关系，评估了原发性T790M突变人群的特征及应用EGFR-TKIs治疗的疗效及预后，同时也关注了第三代EGFR-TKIs的新型继发性耐药问题，为NSCLC的精准治疗提供临床依据和思路。

Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could improve the prognosis of patients with EGFR-mutated non-small cell lung cancer (NSCLC). With the application of TKIs, gene detection found that more and more patients were with EGFR T790M mutations, which significantly affect the treatment and prognosis of NSCLC patients. This article reviews the relation between T790M mutation and EGFR-TKIs, evaluates the population characteristics of primary T790M mutation and the efficacy and prognosis of EGFR-TKIs treatment, as well as pays attention to the new secondary drug resistance of the third generation of EGFR-TKIs, to provide clinical basis and ideas for the precise treatment of NSCLC.